Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Esperion ( (ESPR) ).
On March 2, 2026, Esperion Therapeutics, Inc. signed a definitive agreement to acquire privately held Corstasis Therapeutics Inc. via a merger in which Corstasis will become a wholly owned subsidiary, for an upfront cash payment of $75 million plus up to $180 million in potential regulatory and commercial milestone payments and royalties on future sales. The deal, expected to close in the second quarter of 2026 subject to customary conditions and a May 1, 2026 outside date, consolidates all Corstasis equity into cash consideration tied to upfront, contingent, and escrow-based payments and will be financed through Esperion’s existing credit facilities and royalty monetization arrangements.
Through the acquisition, Esperion will add Enbumyst, the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure and certain hepatic and renal conditions, approved in September 2025, positioning the company to target a U.S. market opportunity exceeding $4 billion and complement its existing cardiovascular franchise. Management frames the transaction as a strategic fit with Esperion’s Vision 2040, aiming to leverage its established cardiovascular commercial infrastructure to drive double-digit revenue growth, expand into outpatient heart failure and fluid overload management, and enhance its presence across metabolic, hepatic, and renal disease, while also gaining Corstasis’s subcutaneous pipeline assets for future market expansion.
On March 3, 2026, Esperion and Corstasis jointly announced the merger agreement and detailed plans to discuss the deal with investors during a conference call the same day. The companies and their advisors highlighted that the transaction’s completion remains subject to typical closing conditions, but is expected to strengthen Esperion’s long-term industry positioning in cardiovascular and renal care by adding a differentiated, home-use diuretic option that may reduce hospitalizations and broaden its stakeholder value proposition.
The most recent analyst rating on (ESPR) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Spark’s Take on ESPR Stock
According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.
The score is held down primarily by weak financial fundamentals—negative equity, sizable leverage, and ongoing cash burn despite improving revenues and narrower losses. Technicals are also soft in the near term (price below short-term averages with low RSI), while valuation provides limited support due to losses and no dividend data. The earnings call was a clear positive with strong growth and franchise protection (generic delay to 2040), but it is not yet sufficient to offset the balance-sheet and cash-flow risks.
To see Spark’s full report on ESPR stock, click here.
More about Esperion
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare or orphan disease therapies, leveraging expertise in ACLY biology to develop and commercialize treatments for patients worldwide. The company currently markets two oral, once-daily, non-statin therapies to help patients manage low-density lipoprotein cholesterol levels and operates a broad U.S. commercial infrastructure with product approvals in more than 40 countries.
Corstasis Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in therapies to manage fluid overload in adults with heart failure, liver disease, and kidney disease, including nephrotic syndrome. Its lead product, Enbumyst (bumetanide nasal spray), a loop diuretic for edema associated with congestive heart failure and hepatic and renal disease, received U.S. Food and Drug Administration approval on September 12, 2025.
Esperion Therapeutics, Inc. operates within the cardiovascular and metabolic disease segment of the pharmaceutical industry, selling prescription therapies targeted at high-risk patient populations. The company is expanding its focus beyond lipid management into broader cardiovascular, hepatic, and renal indications to build a diversified cardiometabolic portfolio and support long-term revenue growth.
Average Trading Volume: 4,673,333
Technical Sentiment Signal: Sell
Current Market Cap: $781.7M
Find detailed analytics on ESPR stock on TipRanks’ Stock Analysis page.